Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company’s multispecific antibodies are designed to harness and direct the power of both innate and adaptive immune systems, providing a safer and more precise alternative to conventional CD3-based therapies. This is made possible by targeting a unique immune cell type: gamma delta T cells.

Gamma delta T cells combine the immediacy of innate immunity with the sustained response of adaptive immunity. Their remarkable ability to distinguish between diseased and healthy cells makes them powerful allies in the fight against cancer. Unlike others who focus on subtype-specific gamma delta T cell therapies, Cytospire says it is the only company developing antibodies capable of targeting all gamma delta T cells—both blood and tissue resident. This differentiated approach allows it to stimulate a broader, more effective immune response across diverse patient populations.

The technology is particularly promising for treating solid tumors. Gamma delta T cells have long been recognized for their role in mounting effective anti-tumor responses. Studies show that patients with a robust gamma delta T cell population often have better outcomes. Cytospire’s first-in-class gamma delta engagers are uniquely positioned to target both blood and tumor-resident gamma delta T cells, offering potent tumor cell killing while sparing healthy tissue and minimizing the risk of cytokine-related adverse events.

With this innovative approach, the UK-based company aims to redefine immune cell engagement, providing hope to patients underserved by current therapies and advancing the next wave of cancer treatment.

Subscribe for alerts on new companies featured on Startups.Bio

View all recently featured startups